Power of the Purse: How a Democratic Congress Plans to Contest Trump's Overhaul of American Science

For nearly two years, the Trump administration has worked to reshape the nation's research infrastructure, proposing steep budget cuts, canceling grants and reorganizing the agencies that have powered American discovery since World War II. After the midterm elections, the political terrain has shifted. Democratic lawmakers, newly empowered by their gains in Congress, are preparing to push back, according to reporting by The New York Times.

The coming fight will not be waged mainly through sweeping new laws, which would still face a presidential veto. It will play out in the less glamorous but more consequential arenas of appropriations, oversight hearings and subpoenas. In Washington, whoever writes the spending bills holds the pen that sketches the federal government's priorities, and that pen is changing hands.

A Budget Battle Years in the Making

The administration's spending blueprints set the stage. Its proposal for the 2026 fiscal year called for cutting the National Institutes of Health by roughly 40 percent and the National Science Foundation by more than half, according to the White House budget documents. Congress, even under Republican control, resisted many of the deepest reductions, but agencies still faced canceled awards, staff departures and a proposed cap on the indirect costs that universities use to keep laboratories running. That cap became the subject of legal challenges.

Researchers have described the period as a slow drain on the scientific pipeline: graduate students leaving for other careers, early-career investigators looking abroad and long-running studies stalled midstream. Rebuilding that pipeline, scientists warn, will take far longer than dismantling it.

What Democrats Can and Cannot Do

With control of the committees that fund the government, Democrats can write appropriations bills that set firm funding levels for research agencies and attach language restricting how money may be redirected or withheld. They can also call agency leaders to testify, demand records on terminated grants and examine whether funds approved by Congress were spent as directed.

The limits are real, however. Any spending bill still requires President Donald Trump's signature, setting up the prospect of tense negotiations and possible shutdown brinkmanship. Agencies retain considerable discretion over which projects they fund, and oversight can expose decisions without necessarily reversing them. Legal disputes over the administration's authority to withhold appropriated money remain unsettled.

The Stakes for Universities and Labs

For universities, hospitals and independent research institutes, the shift offers a measure of predictability after two years of whiplash. Institutional leaders are expected to press lawmakers for multiyear funding commitments and protections for indirect cost reimbursements, which pay for everything from electricity to biosafety compliance.

Republicans are likely to argue that federal research spending has grown bloated and that the administration's changes have forced overdue accountability. That debate over efficiency versus capacity will shape the next round of budget talks.

What emerges is a familiar Washington standoff with unusually high stakes for American science. The administration retains executive levers; Congress now holds a firmer grip on the purse strings. How the two sides reconcile those powers will determine whether the country's research enterprise stabilizes or continues to fray.